Avanos Medical (AVNS) Receivables (2013 - 2026)

Avanos Medical (AVNS) has 14 years of Receivables data on file, last reported at $106.3 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 3.28% year-over-year to $106.3 million; the trailing twelve-month figure through Mar 2026 stood at $106.3 million (down 3.28% YoY), and the FY2025 full-year result was $108.0 million, down 18.67% from the prior year.
• Receivables fell to $106.3 million in Q1 2026, from $108.0 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $167.9 million in Q4 2022 to a low of $106.3 million in Q1 2026.
• A 5-year average of $133.5 million and a median of $132.8 million in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables surged 47.58% in 2022 and fell 19.24% in 2024, its largest moves.
• Tracing AVNS's Receivables over 5 years: stood at $167.9 million in 2022, then decreased by 14.95% to $142.8 million in 2023, then decreased by 7.0% to $132.8 million in 2024, then declined by 18.67% to $108.0 million in 2025, then slipped by 1.57% to $106.3 million in 2026.
• Business Quant data shows AVNS's Receivables at $106.3 million in Q1 2026, $108.0 million in Q4 2025, and $111.5 million in Q3 2025.